[en] Crohn's disease is characterised by recurrent and/or chronic inflammation of the gastrointestinal tract leading to cumulative intestinal tissue damage. Treatment tailoring to try to prevent this tissue damage as well as achieve optimal benefit/risk ratio over the whole disease course is becoming an important aspect of Crohn's disease management. For decades, clinical symptoms have been the main trigger for diagnostic procedures and treatment strategy adaptations. However, the correlation between symptoms and intestinal lesions is only weak. Furthermore, preliminary evidence suggests that a state of remission beyond the simple control of clinical symptoms, and including mucosal healing, may be associated with better disease outcome. Therefore monitoring the disease through the use of endoscopy and cross-sectional imaging is proposed. However, the degree of mucosal or bowel wall healing that needs to be reached to improve disease outcome has not been appropriately studied. Furthermore, owing to their invasive nature and cost, endoscopy and cross-sectional imaging are not optimal tools for the patients or the payers. The use of biomarkers as surrogate markers of intestinal and systemic inflammation might help. Two biomarkers have been most broadly assessed in Crohn's disease: C-reactive protein and faecal calprotectin. These markers correlate significantly with endoscopic lesions, with the risk of relapse and with response to therapy. They could be used to help make decisions about diagnostic procedures and treatment. In particular, with the use of appropriate threshold values, they could determine the need for endoscopic or medical imaging procedures to confirm the disease activity state.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Benitez, Jose-Manuel
Meuwis, Marie-Alice ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
REENAERS, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive
VAN KEMSEKE, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive
Meunier, Paul
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Language :
English
Title :
Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring.
Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohns disease in population-based cohorts. Am J Gastroenterol 2010;105:289-97.
Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohns disease on the need for intestinal surgery. Gut 2005;54:237-41. (Pubitemid 40139240)
Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-22. (Pubitemid 47187355)
Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohns disease. Inflamm Bowel Dis 2009;15:1295-301.
Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohns disease. Gastroenterology 2010;138:463-8.
Rutgeerts P, Van Assche G, Sandborn W J, et al. Adalimumab induces and maintains mucosal healing in patients with Crohns disease: data from the EXTEND trial. Gastroenterology 2012;142:1102-11.
Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohns disease. A prospective multicentre study of 121 cases. The Groupe d?Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994;35:231-5. (Pubitemid 24092870)
Panes J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohns disease. Aliment Pharmacol Ther 2011;34:125-45.
Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;140:1817-26.
Langhorst J, Kühle CA, Ajaj W, et al. MR colonography without bowel purgation for the assessment of inflammatory bowel diseases: diagnostic accuracy and patient acceptance. Inflamm Bowel Dis 2007;13:1001-8. (Pubitemid 47309972)
Terheggen G, Lanyi B, Schanz S, et al. Safety, feasibility, and tolerability of ileocolonoscopy in inflammatory bowel disease. Endoscopy 2008;40:656-63.
Samuel S, Bruining DH, Loftus EV Jr, et al. Endoscopic skipping of the distal terminal ileum in Crohns disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol 2012;10:1253-9.
Colombel J F, Sandborn W J, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohns disease. N Engl J Med 2010;362:1383-95.
Allez M, Lemann M, Bonnet J, et al. Long term outcome of patients with active Crohns disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002;97:947-53. (Pubitemid 34408253)
Prajapati J. Symptomatic luminal strictures underlies infliximab non response in inflammatory bowel disease. Gastroenterology 2002;122:A777.
Mary J Y, Modigliani R. Development and validation of an endoscopic index of the severity for Crohns disease: a prospective multicentre study. Groupe d?Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983-9.
Daperno M, D?Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohns disease: the SES-CD. Gastrointest Endosc 2004;60:505-12. (Pubitemid 39311530)
Hanauer S B, Feagan B G, Lichtenstein G R, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohns disease. Gastroenterology 2010;138:463-8.
Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohns disease treatment: a prospective, randomized clinical trial. The Groupe d?Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992;102:1647-53.
Louis E, Mary J Y, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohns disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142:63-70.
Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohns disease. Gastroenterology 1990;99:956-63. (Pubitemid 20338451)
Bourreille A, Ignjatovic A, Aabakken L, et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy 2009;41:618-37.
Jensen MD, Nathan T, Rafaelsen SR, et al. Diagnostic accuracy of capsule endoscopy for small bowel Crohns disease is superior to that of MR enterography or CT enterography. Clin Gastroenterol Hepatol 2011;9:124-9.
Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohns disease: definitions and diagnosis. J Crohns Colitis 2010;4:7-27.
Horsthuis K, Bipat S, Stokkers PC, et al. Magnetic resonance imaging for evaluation of disease activity in Crohns disease: a systematic review. Eur Radiol 2009;19:1450-60.
Pariente B, Peyrin-Biroulet L, Cohen L, et al. Gastroenterology review and perspective: the role of cross-sectional imaging in evaluating bowel damage in Crohn disease. Am J Roentegenol 2011;197:42-9.
Maconi G, Radice E, Greco S, et al. Bowel ultrasound in Crohns disease. Best Pract Res Clin Gastroenterol 2006;20:93-112.
Bru C, Sans M, Defelitto MM, et al. Hydrocolonic sonography for evaluating inflammatory bowel disease. Am J Roentgenol 2001;177:99-105. (Pubitemid 32578059)
Rimola J, Rodríguez S, García-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohns disease. Gut 2009;58:1113-20.
Rimola J, Ordás I, Rodríguez S, et al. Magnetic resonance imaging for evaluation of Crohns disease: validation of parameters of severity and quantitative index of activity. Bowel Dis 2011;17:1759-67.
Zappa M, Stefanescu C, Cazals-Hatem D, et al. Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohns disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis 2011;17:984-93.
Punwani S, Rodríguez-Justo M, Bainbridge A, et al. Mural inflammation in Crohn disease: location-matched histologic validation of MR imaging features. Radiology 2009;252:712-20.
Gourtsoyiannis NC, Papnikolaou N, Karantanas A. Magnetic resonance imaging evaluation of small intestinal Crohns disease. Best Pract Res Clin Gastroenterol 2006;20:137-56. (Pubitemid 43210631)
Siddiki HA, Fidler JL, Fletcher JG, et al. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohns disease. Am J Roentgenol 2009;193:113-21.
Lee SS, Kim AY, Yang SK, et al. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology 2009;251:751-61.
Paredes JM, Ripolles T, Cortes X, et al. Abdominal sonographic changes after antibody to tumor necrosis factor alpha therapy in Crohns disease. Dig Dis Sci 2010;55:404-10.
Migaleddu V, Scanu AM, Quaia E, et al. Contrast-enhanced ultrasonographic evaluation of inflammatory activity in Crohns disease. Gastroenterology 2009;137:43-52.
Sempere J, Martínez-Sanjuan V, Medina Chulia E, et al. MRI evaluation of inflammatory activity in Crohns disease. Am J Roentegenol 2005;184:1829-35.
Ordás I. Accuracy of MRI to assess therapeutic responses and mucosal healing in Crohns diasease. Gastroenterology 2011;140:S73.
Pariente B, Peyrin-Biroulet L, Cohen L, et al. Gastroenterology review and perspective: the role of cross-sectional imaging in evaluating bowel damage in Crohn disease. Am J Roentegenol 2011;197:42-9.
Giusti S, Faggioni L, Neri E, et al. Dynamic MRI of the small bowel: usefulness of quantitative contrast-enhancement parameters and time-signal intensity curves for differentiating between active and inactive Crohns disease. Abdom Imaging 2010;35:646-53.
Lee SS, Kim AY, Yang SK, et al. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology 2009;251:751-61.
Horsthuis K, Bipat S, Bennink RJ, et al. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology 2008;247:64-79.
Maconi G, Sampietro GM, Parente F, et al. Contrast radiology, computed tomography and ultrasonography in detecting internal fistulas and intraabdominal abscesses in Crohns disease: a prospective comparative study. Am J Gastroenterol 2003;98:1545-55. (Pubitemid 36875346)
Koilakou S, Saliler J, Peloschek P, et al. Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohns disease after ileocolic resection. Inflamm Bowel Dis 2010;16:198-203.
Sailer J, Peloschek P, Reinisch W, et al. Anastomotic recurrence of Crohns disease after ileocolic resection: comparison of MR enteroclysis with endoscopy. Eur Radiol 2008;18:2512-21.
Pariente B, Cosnes J, Danese S, et al. Development of the Crohns disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011;17:1415-22.
Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins ( pentaxins) and serum amyloid A protein. Adv Immunol 1983;34:141-212. (Pubitemid 14089437)
Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohns disease. Gut 2012;61:78-85.
Ramadori G, Christ B. Cytokines and the hepatic acute-phase response. Semin Liver Dis 1999;19:141-55.
Nacken W, Roth J, Sorg C, et al. Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech 2003;60:569-80.
Poullis A, Foster R, Mendall MA, et al. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 2003;18:756-62. (Pubitemid 36936565)
Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002;37:818-24. (Pubitemid 34836819)
Denis M A, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohns disease with normal C-reactive protein serum level. Inflamm Bowel Dis 2007;13:1100-5. (Pubitemid 47402593)
Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohns disease and histological findings. Aliment Pharmacol Ther 2008;28:1221-9.
Bondjemah V, Mary JY, Jones J, et al. Fecal calprotectin and CRP as biomarkers of endoscopic activity in Crohns disease: a meta-study. J Crohn Colitis 2012;6(1): P133.
Sipponen T, Bjorkesten C G, Farkkila M, et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohns disease treatment. Scand J Gastroenterol 2010;45:325-31.
Jürgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohns disease. Clin Gastroenterol Hepatol 2011;9:421-7.
Schoepfer A M, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohns disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162-9.
Jones J, Loftus E V Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohns disease. Clin Gastroenterol Hepatol 2008;6:1218-24.
Wagner M, Peterson CG, Ridefelt P, et al. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008;14:5584-9.
D?Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218-24.
Colombel JF, Solem CA, Sandborn WJ, et al. Quantitative measurement and visual assessment of ileal Crohns disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 2006;55:1561-7. (Pubitemid 44629202)
Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohns disease. Clin Gastroenterol Hepatol 2008;6:1218-24.
Lemann M, Colombel J-F, Grimaud J-C, et al. Fecal calprotectin and high sensitivity c-reactive protein levels to predict mucosal healing in patients with Crohns disease. A subanalysis of the STORI study. Gut 2010;59(uppl III):A80.
Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al. Does fecal calprotectin predict relapse in patients with Crohns disease and ulcerative colitis? J Crohns Colitis 2010;4:144-52.
Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohns disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol 2010;22:340-5.
Tibble J A, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22. (Pubitemid 30452574)
Consigny Y, Modigliani R, Colombel J F, et al. A simple biological score for predicting low risk of short-term relapse in Crohns disease. Inflamm Bowel Dis 2006;12:551-7. (Pubitemid 43977735)
Koelewijn C L, Schwartz M P, Samsom M, et al. C-reactive protein levels during a relapse of Crohns disease are associated with the clinical course of the disease. World J Gastroenterol 2008;14:85-9. (Pubitemid 351314332)
Bitton A, Dobkin PL, Edwardes MD, et al. Predicting relapse in Crohns disease: a biopsychosocial model. Gut 2008;57:1386-92.
De Suray N, Salleron J, Vernier-Massouille G, et al.Close monitoring of CRP and fecal calprotectin levels to predict relapse in Crohns disease patients. A sub-analysis of the STORI study. J Crohn Colitis 2012;6(1):P274.
Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohns disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009;7:80-5.
Regueiro M, Kip KE, Schraut W, et al. Crohns disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis 2011;17:118-26.
Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohns disease. Br J Surg 2009;96:663-74.
